MedPath

Salbutamol

Generic Name
Salbutamol
Brand Names
Airomir, Airsupra, Combivent, Proair, Proventil, Ventolin
Drug Type
Small Molecule
Chemical Formula
C13H21NO3
CAS Number
18559-94-9
Unique Ingredient Identifier
QF8SVZ843E
Background

Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.

Indication

Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm.

Associated Conditions
Asthma, Asthmatic Bronchitis, Bronchial Asthma, Bronchoconstriction, Bronchospasm, Chronic Asthma, Chronic Bronchitis, Cough, Emphysema, Exacerbation of asthma, Exercise-Induced Bronchospasm, Hyperkalemia, Wheezing, Excess mucus or phlegm
Associated Therapies
Airway secretion clearance therapy, Bronchodilation

Salbutamol Use in Ozone Air Pollution by People With Asthma and/or Exercise Induced Bronchoconstriction (EIB)

Phase 4
Recruiting
Conditions
Asthma and/or Exercise Induced Bronchoconstriction
Ozone Air Pollution
Interventions
Drug: Placebo medication
Drug: Salbutamol
Other: Ozone
Other: Filtered Air
Other: Exercise
First Posted Date
2021-10-21
Last Posted Date
2023-05-10
Lead Sponsor
University of British Columbia
Target Recruit Count
30
Registration Number
NCT05087693
Locations
🇨🇦

Environmental Physiology Laboratory, Vancouver, British Columbia, Canada

Inhaled Beta-2 Agonist Versus Epinephrine For Treatment of Transient Tachypnea of Newborn (TTN)

Phase 1
Completed
Conditions
Transient Tachypnea of the Newborn
Interventions
First Posted Date
2021-08-16
Last Posted Date
2021-08-16
Lead Sponsor
Ahmed Noaman
Target Recruit Count
135
Registration Number
NCT05006235

Different Doses of Nebulized Magnesium Sulphate in Status Asthmaticus

Phase 1
Completed
Conditions
Status Asthmaticus
Interventions
Drug: Magnesium Sulfate 500 mg/ml+ ventolin
Drug: Ventolin
First Posted Date
2021-06-18
Last Posted Date
2023-04-05
Lead Sponsor
Ziauddin University
Target Recruit Count
126
Registration Number
NCT04929626
Locations
🇵🇰

Rabia Asif, Karachi, Sindh, Pakistan

Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype

Early Phase 1
Recruiting
Conditions
Primary Ciliary Dyskinesia
Interventions
Drug: Albuterol
Diagnostic Test: Technetium99m - Sulfur Colloid (Tc99m-SC)
First Posted Date
2021-05-25
Last Posted Date
2024-08-26
Lead Sponsor
University of North Carolina, Chapel Hill
Target Recruit Count
30
Registration Number
NCT04901715
Locations
🇺🇸

University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States

Effect of Fluticasone Furoate/Vilanterol on EIA in Adolescents

Phase 4
Completed
Conditions
Asthma in Children
Interventions
First Posted Date
2021-02-11
Last Posted Date
2021-02-11
Lead Sponsor
Rambam Health Care Campus
Target Recruit Count
92
Registration Number
NCT04750603
Locations
🇮🇱

Rambam Medical Center, Haifa, Israel

A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma

Phase 4
Completed
Conditions
Asthma
Interventions
Drug: Fluticasone propionate/salmeterol (FS)
Drug: Standard of Care Asthma Medication
Drug: Standard of Care Rescue Medication
Drug: Albuterol
First Posted Date
2020-12-21
Last Posted Date
2023-03-14
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
427
Registration Number
NCT04677959
Locations
🇺🇸

Teva Investigational Site 14974, Fountain Valley, California, United States

🇺🇸

Teva Investigational Site 14982, Los Angeles, California, United States

🇺🇸

Teva Investigational Site 14955, Fort Lauderdale, Florida, United States

and more 43 locations

Physiologic Performance Response to Salbutamol

Not Applicable
Conditions
Healthy
Interventions
Drug: salbutamol
Drug: Placebo
First Posted Date
2020-11-04
Last Posted Date
2020-11-04
Lead Sponsor
University of Copenhagen
Target Recruit Count
20
Registration Number
NCT04615611

Bronchodilators for Wheeze in Young Children Presenting to Primary Care: a Randomised, Placebo-controlled, Multicentre, Parallel Group Trial

Phase 4
Withdrawn
Conditions
Wheezing
Interventions
Drug: Placebo
Drug: Salbutamol
First Posted Date
2020-10-12
Last Posted Date
2021-07-23
Lead Sponsor
UMC Utrecht
Registration Number
NCT04584034

Mitochondrial Dysfunction and Insulin Resistance in Skeletal Muscle

Not Applicable
Completed
Conditions
Insulin Resistance
Interventions
Drug: Intralipid, 20% Intravenous Emulsion
Dietary Supplement: MitoQ
Drug: Salbutamol
First Posted Date
2020-09-22
Last Posted Date
2021-12-02
Lead Sponsor
University of Copenhagen
Target Recruit Count
10
Registration Number
NCT04558190
Locations
🇩🇰

August Krogh Building, Copenhagen, Denmark

A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD002 in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: ETD002 - 14 day repeat dose
Drug: ETD002 - single dose
Drug: ETD002 - 7 day repeat dose
Drug: Placebo - single dose
Drug: Placebo - 14 day repeat dose
Drug: Placebo - 7 day repeat dose
Drug: Salbutamol
First Posted Date
2020-07-28
Last Posted Date
2021-05-21
Lead Sponsor
Enterprise Therapeutics Ltd
Target Recruit Count
80
Registration Number
NCT04488705
Locations
🇬🇧

Hammersmith Medicines Research, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath